In the News

August 14, 2025

Longevity Technology - Weight loss drugs: ‘Side effects shouldn’t be the price of progress’

August 6, 2025

Applied Clinical Trials - MetaVia Expands GLP-1 Glucagon Receptor Agonist Obesity Trial Amid Signs of Superior Tolerability

August 5, 2025

Pharmaceutical Executive - MetaVia, Syntekabio Partner to Expand Indications for Oral MASH Drug Using AI Drug Discovery

August 4, 2025

First Word Pharma - Metavia taps Syntekabio to explore new avenues for MASH drug with AI

July 29, 2025

Pharmaceutical Commerce - Weighing Cost Savings Against Safety and Regulatory Risks

July 23, 2025

Pharmaceutical Commerce - Can Dual Agonists Deliver Better Outcomes?

July 22, 2025

Pharmaceutical Commerce - Coverage Gaps and Challenges Ahead for Obesity Drugs

July 18, 2025

MedCity News - Turning the Page for Obesity Therapies — Addressing Tolerability and Delivery

July 2, 2025

The Medicine Maker - New Weight-Loss Drug Aims for Results Without Harsh GI Effects

July 1, 2025

Technology Networks Drug Discovery - Beyond the Scale: How Targeted Weight Loss Transforms Metabolic Health and Lowers Healthcare Costs

May 19, 2025

Drug Discovery World - Novel GPR119 agonist shows promise in MASH and diabetes